Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 4/20 | 0.45 |
| ▸ | CTH | P32929 | 1/20 | 0.45 |
| ▸ | CBS | P35520 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20534906 | 1.00 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL81956 | 1.00 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL14950228 | 1.00 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL25495618 | 1.00 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL6664456 | 1.00 | HSD17B10 (0.46) | HSD17B10BLMPMP22TSHRCTH | |
| Hydrochloric Acid SCHEMBL8451150 | 0.97 | THRB (0.48) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL1277996 | 0.97 | HSD17B10 (0.44) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL3796484 | 0.97 | HSD17B10 (0.44) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL45305 | 0.97 | TSHR (0.47) | HSD17B10BLMPMP22TSHRCTH | |
| SCHEMBL25377946 | 0.93 | TSHR (0.45) | HSD17B10BLMPMP22TSHRCTH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0910331-B1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 2004-09-08 | — | — | EP | claimed |
| EP-0910331-A4 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 1999-11-03 | — | — | EP | claimed |
| EP-0910331-A1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1999-04-28 | — | — | EP | claimed |
| US-5834513-A | TOPICAL COMPOSITION FOR TREATING SKIN CONDITIONS CHARACTERIZED BY ABNORMAL DESQUAMATION | AVON PRODUCTS, INC. (US) | 1998-11-10 | — | — | US | claimed |
| WO-1997039726-A1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1997-10-30 | — | — | WO | claimed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent KGaA (DE) | 2025-01-30 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| EP-4426700-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | Merck Patent GmbH (DE) | 2024-09-11 | — | — | EP | disclosed |
| WO-2014084743-A1 | DENDRITIC CORE COMPOUNDS | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-06-05 | — | — | WO | disclosed |
| WO-2014084744-A1 | SACCHARIDE DENDRITIC CLUSTER COMPOUNDS AS INHIBITORS OF BACE-1 | CALLAGHAN INNOVATION RESEARCH LIMITED (NZ) | 2014-06-05 | — | — | WO | disclosed |
| EP-0910331-B1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-0910331-A4 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PROD INC (US) | 1999-11-03 | — | — | EP | disclosed |
| US-5932229-A | TOPICAL COMPOUNDS | AVON PRODUCTS, INC. (US) | 1999-08-03 | — | — | US | disclosed |
| EP-0910331-A1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1999-04-28 | — | — | EP | disclosed |
| US-5834513-A | TOPICAL COMPOSITION FOR TREATING SKIN CONDITIONS CHARACTERIZED BY ABNORMAL DESQUAMATION | AVON PRODUCTS, INC. (US) | 1998-11-10 | — | — | US | disclosed |
| WO-1997039726-A1 | OXA DIACIDS AND RELATED COMPOUNDS FOR TREATING SKIN CONDITIONS | AVON PRODUCTS, INC. (US) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD17B10 2107/4885BLM 1432/4885PMP22 3827/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HSD17B10 2107/4885BLM 1432/4885PMP22 3827/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HSD17B10 2107/4885BLM 1432/4885PMP22 3827/4885 |
| US-20250032625-A1 | HETEROBIFUNCTIONAL MOLECULES AS TEAD INHIBITORS | TEAD1, UBQLN1, TTI1 | HSD17B10 1113/4885BLM 680/4885PMP22 2543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.